Why the study?
Does the SAPIEN S3 valve reduce complications and paravalvular regurgitation compared to the SAPIEN XT valve in patients undergoing TAVI?
Does the SAPIEN S3 valve reduce complications and paravalvular regurgitation compared to the SAPIEN XT valve in patients undergoing TAVI?
The SAPIEN S3 valve improves procedural outcomes by reducing major vascular complications and paravalvular regurgitation, but at the cost of an increased risk for new permanent pacemaker implantation compared to the SAPIEN XT.
AIM: the SAPIEN XT valve (XT-THV). METHODS: We retrospectively analyzed 507 patients that underwent TAVI with the XT-THV and 283 patients that received the S3-THV at our institution between March 2010 and December 2015. CONCLUSION: The S3-THV is associated to lower rates of major vascular complications and PVR but higher rates of new pacemaker compared to the XT-THV. Sub-optimal visualization of the S3-THV in relation to the aortic valvular complex during deployment is a predictor of new permanent pacemaker.
No takes yet. Share an insight, caveat, or question.
Sawaya et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: